Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma.

Publication date: Mar 18, 2020

Open Access PDF

Barailler, H., Salomon, G., Dutriaux, C., Prey, S., G’erard, E., Dousset, L., Mertens, C., Beylot-Barry, M., Meyer, N., and Pham-Ledard, A. Adverse events, need for hospitalization and systemic immunosuppression in very older patients (over 80 years) treated with anti-PD-1 for metastatic melanoma. 26206. 2020 J Geriatr Oncol.

Concepts Keywords
Immunosuppression Melanoma
Melanoma Pembrolizumab
Bristol-Myers Squibb
Nivolumab
Immune system
Antineoplastic drugs
Breakthrough therapy
Cancer treatments
Clinical medicine
Immunosuppression

Semantics

Type Source Name
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
drug DRUGBANK Pembrolizumab
pathway KEGG Melanoma
disease MESH melanoma
drug DRUGBANK Trestolone
disease MESH tumor
disease MESH senescence
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH hypothyroidism
disease MESH colitis
disease MESH opportunistic infection
disease MESH nocardiosis
drug DRUGBANK Mycophenolate mofetil
disease MESH hepatitis
disease MESH renal
disease MESH life style
disease MESH interstitial nephritis
disease MESH complications
disease MESH infection
disease MESH biopsy
drug DRUGBANK Infliximab
disease MESH immuno
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
disease MESH Oncogenesis
disease MESH Lymphoma

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *